A merger deal between Becton Dickinson and C.R. Bard, valued at $24 billion, received approval from C.R. Bard's shareholders. The deal, which could be completed in the fourth quarter if approved by antitrust regulators, will make Bard a new segment of BD called BD Interventional, with Tom Polen serving as president.
$24B Becton Dickinson merger secures C.R. Bard shareholder approval
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.